RaySearch Laboratories AB/Skr RAY B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About RaySearch Laboratories AB
RaySearch Laboratories AB is a medical technology company based in Sweden that specializes in software solutions for radiation therapy used in cancer treatment. The company's primary product is RayStation, an advanced treatment planning system that integrates a comprehensive set of tools for creating radiation therapy plans. Founded in 2000, RaySearch focuses heavily on research and development to innovate in adaptive therapy, automated planning, and machine learning. Its strategic partnerships with major equipment vendors expand its geographic presence, serving clinics and hospitals worldwide. The company's competitive strength lies in its advanced algorithms and focus on improving patient outcomes and treatment workflows.
- Ticker
- Skr RAY B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 464
- Headquarters
- Stockholm, Sweden
- Website
- www.raysearchlabs.com
RAY B Metrics
BasicAdvanced
kr 6.8B
32.56
kr 6.23
0.87
kr 4.00
1.97%
Price and volume
Market cap
kr 6.8B
Beta
0.87
52-week high
kr 264.50
52-week low
kr 153.10
Average daily volume
128K
Dividend rate
kr 4.00
Financial strength
Current ratio
1.288
Quick ratio
1.225
Long term debt to equity
0.356
Total debt to equity
0.456
Dividend payout ratio (TTM)
64.37%
Interest coverage (TTM)
35.69%
Profitability
EBITDA (TTM)
344.3
Gross margin (TTM)
93.02%
Net profit margin (TTM)
16.77%
Operating margin (TTM)
24.73%
Effective tax rate (TTM)
21.49%
Revenue per employee (TTM)
kr 2,740,000
Management effectiveness
Return on assets (TTM)
10.32%
Return on equity (TTM)
26.02%
Valuation
Price to earnings (TTM)
32.558
Price to revenue (TTM)
5.461
Price to book
8.65
Price to tangible book (TTM)
34.59
Price to free cash flow (TTM)
39.425
Free cash flow yield (TTM)
2.54%
Free cash flow per share (TTM)
5.144
Dividend yield (TTM)
1.97%
Forward dividend yield
1.97%
Growth
Revenue change (TTM)
1.39%
Earnings per share change (TTM)
10.73%
3-year revenue growth (CAGR)
10.36%
10-year revenue growth (CAGR)
11.01%
3-year earnings per share growth (CAGR)
59.58%
10-year earnings per share growth (CAGR)
8.47%
10-year dividend per share growth (CAGR)
31.95%
What the Analysts think about RAY B
Analyst ratings (Buy, Hold, Sell) for RaySearch Laboratories AB stock.
Analyst projections of the future price of RaySearch Laboratories AB stock.
Bulls say / Bears say
Order intake rose 23% in Q2, and nine US orders worth about USD 5 million arrived in early Q3 after deals slipped. That supports the view that some delayed demand is converting into sales, although the order pipeline remains uneven. (RaySearch Laboratories, RaySearch Laboratories)
RaySearch’s expanded agreement with Accuray includes an USD 8 million software order and joint marketing of online adaptive radiotherapy. Extending the integration from Radixact towards CyberKnife could open another route to market for RayStation and RayCare. (RaySearch Laboratories)
Clinical use of RayStation and RayCare with Varian TrueBeam is now under way at a US clinic, following online adaptive treatments in Belgium. These live deployments provide evidence that the integrated products can work on widely used equipment and may help RayCare gain adoption. (RaySearch Laboratories, RaySearch Laboratories)
The first half was materially weaker: sales fell 12% and operating profit fell 14% year on year. In Q2 alone, sales dropped 11% and the operating margin was 10%, making the recovery needed to meet the 2026 margin target more demanding. (RaySearch Laboratories)
US hospital purchasing has slowed as reimbursement has fallen and procurement teams have become more cautious, according to the CEO. Longer buying cycles can keep revenue volatile even when deals are delayed rather than cancelled. (StockAnalysis)
China’s push for domestic healthcare equipment and its heavy regulatory process are a stated headwind for RaySearch. Working with local machine vendors may help, but the company still faces a tougher route to growth in that market. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
RAY B Financial Performance
Revenues and expenses
RAY B Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RAY B
Fund name | Fund size | Skr RAY B weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.06% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.06% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.